290 related articles for article (PubMed ID: 34779643)
1. Research progress on the treatment of advanced prostate cancer with Olaparib.
Su YX; Yu CF; Xue P; Li LL; Xiao KM; Chu XL; Zhu SJ
Neoplasma; 2021 Nov; 68(6):1132-1138. PubMed ID: 34779643
[TBL] [Abstract][Full Text] [Related]
2. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
Zhu Q; Chen J; Liu H; Zhao J; Xu C; Sun G; Zeng H
BMC Cancer; 2024 Jun; 24(1):706. PubMed ID: 38851712
[TBL] [Abstract][Full Text] [Related]
4. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
5. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
6. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
7. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
8. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Adashek JJ; Jain RK; Zhang J
Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
[TBL] [Abstract][Full Text] [Related]
9. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
Messina C; Giunta EF; Signori A; Rebuzzi SE; Banna GL; Maniam A; Buti S; Cattrini C; Fornarini G; Bauckneht M; Greystoke A; Plummer R; Oing C; Rescigno P
Eur Urol Oncol; 2024 Apr; 7(2):179-188. PubMed ID: 37574390
[TBL] [Abstract][Full Text] [Related]
10. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
11. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
[TBL] [Abstract][Full Text] [Related]
13. Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?
VanderWeele DJ; Hussain M
NEJM Evid; 2022 Sep; 1(9):EVIDe2200154. PubMed ID: 38319811
[TBL] [Abstract][Full Text] [Related]
14. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
15. Stratifying prostate patients for olaparib.
Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
VanderWeele DJ; Hussain M
Clin Adv Hematol Oncol; 2020 Dec; 18(12):808-815. PubMed ID: 33406057
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.
LeVee A; Lin CY; Posadas E; Figlin R; Bhowmick NA; Di Vizio D; Ellis L; Rosser CJ; Freeman MR; Theodorescu D; Freedland SJ; Gong J
Onco Targets Ther; 2021; 14():4819-4832. PubMed ID: 34552338
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
Bieńkowski M; Tomasik B; Braun M; Jassem J
Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
[TBL] [Abstract][Full Text] [Related]
19. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
Labriola MK; Atiq S; Hirshman N; Bitting RL
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer and PARP inhibitors: progress and challenges.
Teyssonneau D; Margot H; Cabart M; Anonnay M; Sargos P; Vuong NS; Soubeyran I; Sevenet N; Roubaud G
J Hematol Oncol; 2021 Mar; 14(1):51. PubMed ID: 33781305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]